当前位置: 首页 > 期刊 > 《新医学》 > 20188
编号:13575782
肝硬化合并门静脉血栓的患者应用纤溶酶溶栓的疗效研究(4)
http://www.100md.com 2018年8月1日 《新医学》 20188
     [15]Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA.Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation.Dig Dis Sci,58(6):1776-1780.

    [16]方皓,杨正德,王德宇,付国静,李心红.肝硬化并发门静脉血栓的治疗进展.胃肠病学和肝脏病学杂志,2015,24(8):1030-1032.

    [17]Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, Vizzini G, Tuzzolino F, Gridelli B, Bosch J. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut,2011,60(6):846-852.

    [18]陈东风,熊吉.肝硬化门静脉血栓形成的机制与治疗进展.临床肝胆病杂志,2017,33(3):451-453.

    [19]Henao EA, Bohannon WT, Silva MB Jr. Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator.J Vasc Surg,2003,38(6):1411-1415.

    [20]湯照峰,邓美海,凌云彪,邓鹏,许瑞云.早期抗凝、祛聚预防门静脉高压症脾脾切除术后门静脉血栓形成.中华肝胆外科杂志,2008,14(2):85-87.

    (收稿日期:2018-03-28)

    (本文编辑:杨江瑜), 百拇医药(许洁娜 邝乃乐 区卫林 尹合坤)
上一页1 2 3 4